Nine of every 10 medical aid users will see increases averaging 7.9% for 2027, double the Council for Medical Schemes’ 3.8% guideline, with schemes citing solvency needs.
The CMS recommendation is a guideline, not a ceiling. Schemes justify higher increases by referencing their financial positions, solvency requirements, and demographic risk profiles, Moneyweb reported. This framework allows for increases of 7%, 8%, or even 9%. The five largest open schemes, which comprise over 87% of medical aid beneficiaries, have collectively announced weighted increases near that upper threshold.
The increases are not uniform, with significant variance between plans and providers. This variability makes it difficult for beneficiaries to choose options during the annual change period.
The weighted averages are calculated as follows. The increases are calculated based on the number of beneficiaries on each plan, meaning a large increase on a smaller plan has less impact on the scheme’s overall average than the same increase on a plan with millions of members. The data reveals a clear market structure where a few dominant players set the pace for the entire industry.
Medical Aid Contributions Rise 7.9%
- Medical aid contributions for 2027 will increase by an average of 7.9% across major schemes, significantly outpacing the 3.8% CMS guideline.
- The increases are not evenly distributed, with entry-level and comprehensive plans seeing the highest hikes, up to 17% for specific Bestmed bands.
- Discovery Health Medical Scheme (DHMS) is countering price pressure with a new low-cost entry-level plan, Active Core, positioned 26% below comparable market averages.
How the Top Schemes Justify Double-Digit Hikes
The CMS recommendation of 3.8% serves as an anchor, not a limit. The regulatory framework explicitly allows schemes to exceed this figure. As Moneyweb detailed, the CMS circular states any additional provision for solvency must be “supported by each scheme’s financial position, solvency needs, and demographic risk profile.” This clause is the critical loophole enabling increases that are more than double the suggested baseline.
The financial position of these schemes is paramount.
The demographic risk profile is another key factor. Schemes with a higher concentration of older members or those with chronic conditions face inherently higher claims costs.
Plan-Specific Breakdown: From Entry-Level to Comprehensive
A granular analysis of the top five schemes reveals that the largest increases are clustered at opposite ends of the product spectrum: the most comprehensive plans with extended benefits, and the entry-level plans for lower-income earners. This dichotomy highlights a core market tension.
According to a Moneyweb analysis, there are nine plans across the top five schemes where contributions will increase by more than 10%. These include Bonitas Medical Fund‘s BonComprehensive (10.2%), BonClassic (10.2%), and Hospital Standard (10.2%) plans. The most significant increases are Bonitas’s four BonCap plans across all income bands, which will see a uniform 11.5% rise.
The situation is particularly acute at Bestmed Medical Scheme. A consolidation of its income-dependent Rhythm 2 plan bands has led to extreme spikes. The entry-level band for Rhythm 2 faces a 17% increase, while the middle band jumps by 14%.
DHMS Introduces Low-Cost Plan Active Core
In response to this pricing pressure, Discovery Health Medical Scheme (DHMS) is strategically launching a new, more affordable option. DHMS will introduce Active Core in 2027, with a primary member contribution of R1,700 per month.
According to the company, “a family of three will pay R3,750 a month,” which it claims is “at least 26% below the average contribution of the seven closest comparable plans.” The child dependent contribution of R500 is positioned as “the lowest in the open medical scheme market.”
This launch is part of a broader strategy by DHMS to capture price-sensitive consumers. The new plan follows the launch of Active Smart in 2025 and Essential Smart Saver in 2026, creating a tiered product portfolio designed to offer entry points at various price levels while maintaining its dominant market share. This competitive move puts pressure on rivals like Bonitas and Bestmed, who are instead implementing broad-based increases across their portfolios.
| Scheme | Market Share | 2027 Weighted Increase | 2027 Increase Range |
|---|---|---|---|
| Discovery Health Medical Scheme | 58% | 8.2% | 7.4% – 8.9% |
| Bonitas Medical Fund | 15% | 8.7% | 7.3% – 11.5% |
| Momentum Medical Scheme | 5.5% | 7.9% | 7.2% – 8.5% |
| Bestmed Medical Scheme | 4.8% | 7.35% | 6.5% – 17% |
| Medihelp Medical Scheme | 4% | 7.5% | 6.5% – 8.5% |
What Comes Next for Medical Aid Beneficiaries
The annual window to switch plans is critical, as the new contribution rates take effect at the start of the 2027 benefit year. Because increases vary widely, a member on a low-end plan at one scheme could find a more affordable option at another, or vice-versa.
Across the five major schemes, only one new plan is being launched for 2027: DHMS’s Active Core.
The CMS guideline of 3.8% has proven to be a theoretical floor, not a practical ceiling.
“The CMS recommendation is a guideline and is not prescriptive,” a spokesperson for the Council for Medical Schemes noted, reiterating the flexible nature of the regulatory framework that allows schemes to adjust based on their unique financial and risk profiles.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.